NextPharma Technologies Göttingen Facility In Germany Adds New Bottle Filling Line For Tablets
NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotechnology industries, is pleased to announce that its Göttingen facility, a centre of excellence for dry dosage forms, has added a new bottle filling line for tablets.
This 45 metre ‘U-Form' line is constructed with a completely separate primary area for filling and sealing and secondary area for labelling and packaging. This new addition meets highest GMP/FDA standards and is a significant addition to the packaging technologies for solid dosage forms at NextPharma's Göttingen site.
This line which has also been designed to serve the US market can fill different forms of tablets, capsules and coated tablets into plastic and glass bottles of differing forms and sizes. Currently, the line is set up to provide six bottling formats and further formats can be added as required. Round or square bottles can be bundled or packed directly into boxes on the line and can be sealed with screw-caps or press-on caps with tamper proof or childproof sealings. The labelling unit can also provide a number of different formats including a printed Data-Matrix Code.
The line's flexible set up can be adapted to meet customer requirements including providing desiccant conditions, filling material insertions such as foam, induction sealings, packaging for special shipping or presentation cartons with Data-Matrix Code printing.
Dr. Hermann Osterwald, Managing Director, NextPharma Technologies, Contract Manufacturing Services (CMS) commented: "We are pleased to have added this new facility to our already extensive solid dosage manufacturing and packaging facility in Göttingen which maximises further our flexibility to meet customer requirements.
Bill Wedlake, Chief Executive Officer of NextPharma added "The refurbishment of this facility to provide a centre of excellence for the manufacture and packaging of solid dosage forms has been a key priority for NextPharma and I'm delighted that the process is now complete following the arrival of this new bottle filling line. We are excited at the prospect of also serving the US market in this area of contract manufacturing and meeting our customers' requirements through our expanded capabilities in this excellent facility".
NextPharma Göttingen has many years of experience in the manufacture and packaging of solid dosage forms. It was established as a centre of excellence for manufacturing and packaging conventional solid dosage forms following its extensive refurbishment in 2007. In addition to tablets and hard gelatin capsules it can manufacture and package effervescent tablets and sachets and provide Alu-Alu blister packaging. Additionally, Göttingen can provide, Clinical Trial Packaging, pharmaceutical development and microbiological testing.
NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers including solids, liquids and semi-solid dosage forms, antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing (lyophilized and liquid fill), with particular expertise in product development and manufacture of oncology medicines.
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry.
We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally we have significant expertise in paediatric drug formulation, development and manufacture.
We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.
We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.
We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.
All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.
SOURCE: NextPharma